Moderna (NASDAQ:MRNA – Get Free Report) had its price objective lowered by analysts at JPMorgan Chase & Co. from $40.00 to ...

Shares of Moderna, Inc. (NASDAQ:MRNA – Get Free Report) have been assigned an average rating of “Hold” from the twenty-four ...

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

Moderna (MRNA) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we ...

Klinger joined the Cambridge, Massachusetts-based pharmaceutical company in 2021, when Moderna's stock was trading at around ...

Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

Shares of Moderna are currently trading below their 200-day and 50-day moving averages. The stock’s poor price performance has left investors wondering whether to buy, hold or sell it.

Moderna’s stock and future vaccine research programs ... and four Sells assigned in the last three months. The average MRNA price target of $42.93 implies a 41.4% upside from current levels.

Moderna has gotten torched over the last six months - since September 2024, its stock price has dropped 51.2% to $33.99 per share. This was partly due to its softer quarterly results and might ...

Here are five things you should know if you're considering buying Moderna stock now. Moderna is recognized ... valuation of roughly 4 times sales as a price-to-sales (P/S) ratio, offering a ...